Medigene AG (WBO:MDG1) Debt-to-EBITDA : -0.19 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Medigene AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medigene AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.91 Mil. Medigene AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2.04 Mil. Medigene AG's annualized EBITDA for the quarter that ended in Dec. 2023 was €-15.76 Mil. Medigene AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.19.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medigene AG's Debt-to-EBITDA or its related term are showing as below:

WBO:MDG1' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.62 Med: -0.2 Max: 0.28
Current: -0.2

During the past 13 years, the highest Debt-to-EBITDA Ratio of Medigene AG was 0.28. The lowest was -0.62. And the median was -0.20.

WBO:MDG1's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.39 vs WBO:MDG1: -0.20

Medigene AG Debt-to-EBITDA Historical Data

The historical data trend for Medigene AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Debt-to-EBITDA Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.35

-0.24

-0.62

0.28

-0.20

Medigene AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.98	0.11	-0.84	-0.25	-0.19

Competitive Comparison of Medigene AG's Debt-to-EBITDA

For the Biotechnology subindustry, Medigene AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigene AG's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medigene AG's Debt-to-EBITDA falls into.

Medigene AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medigene AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.914	+	2.036)	/	-14.581
	=	-0.20

Medigene AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.914	+	2.036)	/	-15.758
	=	-0.19

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Medigene AG (WBO:MDG1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Medigene AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medigene AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG (WBO:MDG1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (WBO:MDG1) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

MDGEF:USA MDG1:Germany

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (WBO:MDG1) Headlines

No Headlines